Blog / Archives
ASCO: Little Help for Biotech Stocks
Two Big Winners in Bristol Myers Squibb and Celgene The American Society of Oncology Meeting is normally good times for biotech as scientific and clinical developments propel stocks. This year the...
Cubist (CBST) Pharmaceuticals Up 3% on Heavy Volume
In a nasty market where many indices are down 2.5% or more Cubist bucks the trend up 3% apparently on a Cowen and Co. upgrade from Neutral to Outperform.As of midday trading with a Volume of 2.8M...
Genetic Testing Gets a Boost From Medco(MHS)
Diagnostic Medicine is on the Forefront Genetic tests and the new field of pharmacogenomics is getting marketing support from an unlikely source-Pharmacy Benefit Managers (PBM's). Medco (MHS), a...
Pathway Genomics Makes Giant Marketing Step in Personalized Medicine
Genotyping on a Fast Track Direct to Consumer Pathway Genomics is offering a "Health Kit" that reports your genetic risk for 70 diseases such as Cancer,Cardiovascular Disease,RA,and Diabetes....
Response Genetics(RGDX) Signs Agreement with Glaxo for BRAF Gene
Response Genetics(RGDX) announced a deal today for a non-exclusive license to provide GlaxoSmithKline (GSK) with certain rights to proprietary BRAF mutational analysis technology in human tumor...
Biomarkers Drive Personalized Medicine
Companion Diagnostics Enable More Targeted Therapy At the 2010 BIO Conference in Chicago with about 15,000 attendees there were ten Breakout Sessions on Biomarkers (BM) encompassing Intellectual...
Dendreon(DNDN) Receives FDA Approval for Therapeutic Cancer Vaccine
New Treatment Category for Cancer-Autologous Cellular Immunotherapy The FDA cleared the first therapeutic vaccine for cancer with Dendreon's Provenge (R)(Sipuleucel-T), an individualized treatment...
Milken Institute Global Conference-Healthcare Reform I
Missed Opportunity in Health Reform-Wellness and Prevention On Monday April 26 a panel of executives and leaders including Michael Milken, moderated by CNBC anchor Maria Bartiromo convened to...
Gilead(GILD) and Abbott(ABT) Guidance Triggers Biotech Sell-Off
Healthcare Reform Impact on Gilead HIV Product Sales Surprises Analysts Gilead Sciences (GILD) lowered its 2010 sales forecast to a range of $7.4-$7.5B from $7.6-$7.8B citing recently enacted...
Genomics Update from AACR: Biomarkers for Oncology Medicine
Yesterday we presented an overview of the use of Biomarkers(BM's) for predictive use in the treatment of Lung Cancer. Here are some additional summaries from the American Association for Cancer...